Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Expression Genetics, Inc.
Huntsville, Alabama, United Statesgenome.gov ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Expression Genetics, Inc. developed proprietary biocompatible polymer-based platforms to deliver nucleic acid therapeutics. Its lead product EGEN‑001—a nonviral IL‑12 gene therapy—completed Phase I monotherapy trials in ovarian cancer with promising results and entered a combination trial with chemotherapy. The company also advanced preclinical programs using its TheraSilence™ technology to deliver siRNA/shRNA against various disease targets including cancers and cardiovascular conditions. EGEN‑001 received FDA Orphan Drug Status in 2005 and an FDA Orphan Grant in 2007.
- Therapeutic areas
- OncologyCardiovascular
- Modalities
- DNA therapeutics (gene therapy)RNAi therapeutics (siRNA, shRNA)Plasmid-based gene deliveryCytokine gene therapy (IL-12 plasmid)Biocompatible polymer delivery systems
- Industry
- Biotech
02
Partnerships
Collaborations with outside investigators, biotech organizations, universities on research projects related to nucleic acid therapeutics
Beyond the preview
Go deeper on Expression Genetics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Expression Genetics, Inc..